GEHC Stock Analysis: GE HealthCare Technologies | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 31.815m USD | 12M Return: -3.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 345M
EPS Trend: 84.2%
Qual. Beats: 0
Rev. Trend: 82.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 3.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is a U.S.-based medical technology company that develops, manufactures, and markets diagnostic imaging, patient care, and pharmaceutical diagnostic products, services, and digital solutions. Spun off from General Electric in early 2023, the company is headquartered in Chicago and operates in the U.S., Canada, and international markets.
The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging, and womens health), Advanced Visualization Solutions (ultrasound, image-guided therapies, and surgical visualization), Patient Care Solutions (monitoring, diagnostic cardiology, anesthesia, and maternal infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals for radiology and nuclear medicine). The PDx segment supplies diagnostic agents used to enhance tissue visibility during imaging exams, and the company maintains a strategic collaboration with DeepHealth.
Within the health care equipment industry, GE HealthCare competes in a concentrated global market alongside other major imaging and diagnostic equipment manufacturers, where scale, installed-base service revenue, and recurring consumables and radiopharmaceutical sales typically drive margin performance.
- Imaging orders rebound as hospital capital spending recovers
- Contrast media supply tightness lifts Pharmaceutical Diagnostics margins
- Buyback execution supports earnings amid Siemens and Philips competition
| Net Income: 1.59b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.01 > 1.0 |
| NWC/Revenue: 0.82% < 20% (prev 5.85%; Δ -5.02% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.42b > Net Income 1.59b |
| Net Debt (8.44b) to EBITDA (3.18b): 2.65 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (454.0m) vs 12m ago -0.87% < -2% |
| Gross Margin: 42.91% > 18% (prev 41.55%; Δ 1.37% > 0.5%) |
| Asset Turnover: 55.65% > 50% (prev 56.24%; Δ -0.59% > 0%) |
| Interest Coverage Ratio: 5.90 > 6 (EBIT TTM 2.57b / Interest Expense TTM 436.0m) |
| A: 0.00 (Total Current Assets 8.47b - Total Current Liabilities 8.30b) / Total Assets 37.2b |
| B: 0.17 (Retained Earnings 6.20b / Total Assets 37.2b) |
| C: 0.07 (EBIT TTM 2.57b / Avg Total Assets 36.4b) |
| D: 0.42 (Book Value of Equity 11.0b / Total Liabilities 26.3b) |
| Altman-Z'' = 1.49 = BB |
| DSRI: 0.86 (Receivables 3.88b/4.47b, Revenue 20.2b/20.0b) |
| GMI: 0.97 (GM 41.55% / 42.91%) |
| AQI: 1.13 (AQ_t 0.69 / AQ_t-1 0.61) |
| SGI: 1.01 (Revenue 20.2b / 20.0b) |
| TATA: 0.00 (NI 1.59b - CFO 1.42b) / TA 37.2b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of August 03, 2026, the stock is trading at USD 68.02 with a total of 4,922,333 shares traded. Over the past week, the price has changed by +12.28%, over one month by +3.80%, over three months by +11.57% and over the past year by -3.53%.
Current recommended Stop Loss: 64.10 (which is 5.8% or 1.5 ATR below the current price).
GE HealthCare Technologies has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.7 | 20.1% |
P/E Trailing = 16.5735
P/E Forward = 14.7059
P/S = 1.5165
P/B = 2.9591
P/EG = 2.0281
Revenue TTM = 20.2b USD
EBIT TTM = 2.57b USD
EBITDA TTM = 3.18b USD
Long Term Debt = 10.1b USD (from longTermDebt, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 10.5b USD (from shortLongTermDebtTotal, last quarter) + Leases 448.0m
Net Debt = 8.44b USD (calculated: Debt 10.5b - CCE 2.10b)
Enterprise Value = 40.3b USD (31.8b + Debt 10.5b - CCE 2.10b)
Interest Coverage Ratio = 5.90 (Ebit TTM 2.57b / Interest Expense TTM 436.0m)
EV/FCF = 44.97x (Enterprise Value 40.3b / FCF TTM 895.0m)
FCF Yield = 2.22% (FCF TTM 895.0m / Enterprise Value 40.3b)
FCF Margin = 4.42% (FCF TTM 895.0m / Revenue TTM 20.2b)
Net Margin = 7.86% (Net Income TTM 1.59b / Revenue TTM 20.2b)
Gross Margin = 42.91% ((Revenue TTM 20.2b - Cost of Revenue TTM 11.6b) / Revenue TTM)
Gross Margin QoQ = 41.17% (prev 38.53%)
Tobins Q-Ratio = 1.08 (Enterprise Value 40.3b / Total Assets 37.2b)
Interest Expense / Debt = 4.14% (Interest Expense 436.0m / Debt 10.5b)
Taxrate = 21.83% (446.0m / 2.04b)
NOPAT = 2.01b (EBIT 2.57b * (1 - 21.83%))
Current Ratio = 1.02 (Total Current Assets 8.47b / Total Current Liabilities 8.30b)
Debt / Equity = 0.96 (Debt 10.5b / totalStockholderEquity, last quarter 11.0b)
Debt / EBITDA = 2.65 (Net Debt 8.44b / EBITDA 3.18b)
Debt / FCF = 9.43 (Net Debt 8.44b / FCF TTM 895.0m)
Total Stockholder Equity = 10.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.38% (Net Income 1.59b / Total Assets 37.2b)
RoE = 15.16% (Net Income TTM 1.59b / Total Stockholder Equity 10.5b)
RoCE = 12.48% (EBIT 2.57b / Capital Employed (Equity 10.5b + L.T.Debt 10.1b))
RoIC = 7.19% (NOPAT 2.01b / Invested Capital 27.9b)
WACC = 7.78% (E(31.8b)/V(42.4b) * Re(9.29%) + D(10.5b)/V(42.4b) * Rd(4.14%) * (1-Tc(0.22)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.02 | Cagr: -0.49%
[DCF] Terminal Value 73.10% ; FCFF base≈1.16b ; Y1≈1.02b ; Y5≈824.0m
[DCF] Fair Price = 10.53 (EV 13.2b - Net Debt 8.44b = Equity 4.79b / Shares 454.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 84.21 | EPS CAGR: 7.39% | SUE: 0.82 | # QB: 0
Revenue Correlation: 82.55 | Revenue CAGR: 1.42% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.21 | Chg30d=-2.94% | Revisions=-27% | Analysts=14
EPS current Year (2026-12-31): EPS=4.92 | Chg30d=+0.93% | Revisions=-29% | GrowthEPS=+7.1% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=5.41 | Chg30d=+0.87% | Revisions=-44% | GrowthEPS=+10.0% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -40% (up=6, down=16)